Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17302205 | 0.80 | L3MBTL1 (0.36) | L3MBTL1MEN1GLATSHRHTT | |
| SCHEMBL17302068 | 0.77 | L3MBTL1 (0.41) | L3MBTL1MEN1KMT2AHTR1ADRD2 | |
| SCHEMBL10958985 | 0.72 | HSP90AB1 (0.36) | HTR1ADRD2 | |
| SCHEMBL11604294 | 0.69 | TDP1 (0.39) | L3MBTL1MEN1GLATSHRHTT | |
| SCHEMBL1397057 | 0.69 | ALDH1A1 (0.39) | TSHRHTR1ADRD2 | |
| SCHEMBL7202819 | 0.69 | HTR1A (0.31) | HTR1ADRD2 | |
| SCHEMBL11021418 | 0.68 | CYP1A2 (0.36) | L3MBTL1MEN1GLATSHRHTT | |
| SCHEMBL18661654 | 0.68 | L3MBTL1 (0.33) | L3MBTL1MEN1GLATSHRHTT | |
| SCHEMBL28960187 | 0.67 | KMT2A (0.37) | L3MBTL1MEN1KMT2AHTR1ADRD2 | |
| SCHEMBL9507188 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906932-B2 | Cyclising peptides | THE UNIVERSITY OF DURHAM (GB) | 2021-02-02 | — | — | US | disclosed |
| US-20170204134-A1 | Cyclising Peptides | THE UNIVERSITY OF DURHAM (GB) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906932-B2 | Cyclising peptides | VIP, NGLY1, NPPA | L3MBTL1 1882/4885MEN1 151/4885GLA 3711/4885 |
| US-20170204134-A1 | Cyclising Peptides | VIP, NGLY1, NPPA | L3MBTL1 1882/4885MEN1 151/4885GLA 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.